New drug cocktail takes on hard-to-treat lymphomas

NCT ID NCT03240211

Ongoing Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether combining the immunotherapy pembrolizumab (Keytruda) with chemotherapy drugs pralatrexate and decitabine is safe and can shrink tumors in people with relapsed peripheral or cutaneous T-cell lymphoma. About 37 adults whose cancer has returned or not responded to prior treatments will receive different drug combinations. The main goals are to find the best dose and check for early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (Keytruda), pralatrexate (Folotyn), and decitabine (Dacogen)
What this could lead to: If successful, this could point toward a new combination treatment for people with relapsed T-cell lymphoma that has stopped responding to standard therapy.
What could go wrong: This is a very early phase 1 trial with only 37 participants, so the main goal is finding a safe dose, not proving it works. Side effects from the drug combinations could be serious, and the approach may not shrink tumors or extend survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTCL PTCL

Contacts and locations

Locations

Allegheny Health Network

Pittsburgh, Pennsylvania, 15212-4722, United States
University of Virginia

Charlottesville, Virginia, 22911, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.